Clinical Trial

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2023-11-16; most recent amendment 2026-03-30.
Trial Details
NCT Number NCT06144606
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Kite, A Gilead Company
Conditions B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia
Enrollment 60 participants
Start Date 2023-12-26
Primary Completion 2028-11-15 (estimated)
Study Completion 2028-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-03-31